HIV-VAC, Inc.'s Dr. Gordon Skinner Files Patent Application for a New HIV Vaccine Business Wire
click here to return to Business Wire main menu
DonateNow
Print this Article


HIV-VAC, Inc.'s Dr. Gordon Skinner Files Patent Application for a New HIV Vaccine

Business Wire - April 2, 2003

TORONTO--HIV-VAC, Inc announced today that Dr. Gordon Skinner, MD(Hons) the Director of Research of HIV-VAC and the original developer of HIV-VAC's proposed vaccine (NFU.Ac.HIV1RU1295(JM)) designed to combat HIV/AIDS, has, in conjunction with Intracell Vaccines Ltd, filed a patent application with the United Kingdom Patent and Trademark Office for a method of inhibiting the release of HIV from an HIV-infected cell. This application covers what HIV-VAC believes is a novel method of vaccine preparation and use. The proposed new vaccine will operate by a different defense mechanism and will also reduce manufacturing costs. The proposed new vaccine complements the vaccine that HIV-VAC is currently marketing and initial studies indicate that the proposed new vaccine might offer more breadth of protection since it is not dependent on individual strains of HIV and could possibly be effective against all strains of the HIV virus. Development work on the proposed new vaccine will continue for approximately one year after which HIV-VAC expects that it will be tested in a Phase I Trial.

Although the patent for the new proposed vaccine is not being filed by HIV-VAC, under the license acquisition agreement dated April 6, 1999, between HIV-VAC and Intracell Vaccines Ltd, HIV-VAC will have the exclusive worldwide rights to the use of the vaccine as it relates to HIV/AIDS. Dr. Skinner, along with HIV-VAC's CEO Kevin Murray and Vice President John Palethorpe, each equally own all of the outstanding shares of common stock of Intracell Vaccines Ltd.

HIV-VAC, Inc. is a development stage BioTech company in the business of developing and marketing a vaccine intended to combat HIV/AIDS. The company has completed pre-clinical trials in the UK and Russia on the vaccine NFU.Ac.HIV1RU1295(JM), and is expects to be able to initiate Phase I/II trial within the next 6 months.

The information contained in this press release, including any "forward looking" statements within the meaning of section 27A of the securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-KSB and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related to that are unpredictable and outside of the influence and/or control of the Company. In particular, these risks and uncertainties include, without limitation: that third parties may be successful in challenging the patent issued; that granted claims may be held invalid or interpreted differently by a court of law; that other patents will issue that will block the Company from commercializing the technology covered by the patents; and that the benefits that Company believes can be derived from the patented technology will not be realized due to difficulties encountered in the long and expensive process of the development of new technologies and the cost and uncertainty in obtaining regulatory approval for products based on these technologies. In addition, there are many other risks and uncertainties inherent in the development of the Company's products, including the risk of not obtaining regulatory approval for a variety of reasons and the risk of adverse side effects in humans. Other risks relating to Company are detailed from time to time in documents filed by Company with the SEC.

Note to Editors: In "NFU.Ac.HIV1RU1295(JM)" mentioned in this release, the "RU1295" should be subscript.

CONTACT: HIV-VAC, Inc.

Kevin W. Murray, 705/444-6317

SOURCE: HIV-VAC, Inc.


030402
BW030402

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .